Current stock page

Stock Analysis

Erasca, Inc. (ERAS) Stock Analysis

Erasca, Inc. (ERAS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

ERAS Stock Analysis Summary

Erasca, Inc. (ERAS) currently has an AIQ Score of 61/100, indicating a neutral setup. Momentum is the strongest factor at 67/100. Risk is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

ERAS at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$15.66
AIQ Score61/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Buy
Market Cap$5.39B
P/E Ratio (TTM)-15.82
Forward P/E—
EPS (Q3 FY2026)-$0.15
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.62
Volume8.53M
52-week range$2.46-$24.28
RSI 1453.84
50-Day SMA$14.96
200-Day SMA$15.26
Analyst Price Target—
Next EarningsMar 11, 2027
As of Nov 13, 2026 · Market close

ERASErasca, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Sector Leader

NeutralEdge 10/10
$15.66−$0.12 (−0.76%)

Latest quote

  • Momentum
    67
  • Value
    —
  • Quality
    65
  • Risk resilience
    39
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

ERAS Stock Analysis Summary

Erasca, Inc. (ERAS) currently has an AIQ Score of 61/100, indicating a neutral setup. Momentum is the strongest factor at 67/100. Risk resilience is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, ERAS has AIQ Score of 61/100 with Momentum base of 67/100 and fading Risk resilience at 39/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (67/100) leads while Risk resilience (39/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.76% stock move · ERAS classified in Biotechnology.

Current Evidence

NeutralERAS is in a neutral AIQ regime; Momentum is the strongest visible factor at 67/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is ERAS Bullish or Bearish Right Now?

ERAS currently has a neutral overall setup. Momentum is the strongest factor at 67/100, while Risk Resilience is weakest at 39/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Quality is supportive at 65/100.
  • - Momentum is constructive at 67/100.
  • - Price is +4.70% above its 50-day SMA.
  • - Technical consensus has more buy votes than sell votes (30 vs 6).
Bear Case
  • - Risk Resilience is weak at 39/100.

Current Consensus

ERAS's Technical Analysis Consensus is currently Strong Buy, with 30 buy, 10 neutral, and 6 sell votes. ERAS's 14-day RSI is 53.84, which places the stock in a neutral momentum range. ERAS's beta is 1.62, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in ERAS?

The largest recent change in ERAS is Quality moving up by 21.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+10.0
Momentum
+4.0
Quality
+21.0
Risk
+1.0

What Would Change the ERAS Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

ERAS Decision Framework

Public evidence layers, setup checks, and risk context for Erasca, Inc..

Erasca, Inc. (ERAS) Stock Analysis

Erasca, Inc. has an AIQ Score of 61/100 in a Neutral regime. Momentum is strongest at 67/100. Beta is 1.62, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextERAS is in a Neutral AIQ regime with score 61/100.
Signal ConflictThe primary conflict is that momentum leads at 67/100 while risk lags at 39/100.
Factor EvidenceMomentum 67/100 · Quality 65/100 · Risk 39/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 67/100.

TimingPass

Momentum is 67/100 and RSI (14) is 53.8.

Regime fitWait

ERAS is in a Neutral regime at 61/100.

Risk controlFail

Risk factor is 39/100 with beta 1.62 and annual volatility 102.7%.

ConflictWait

Current conflict: momentum leads at 67/100 while risk lags at 39/100.

AIQ Score
61/100
Price
$15.66
Beta
1.62
RSI (14)
53.8

ERAS Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

ERAS Fundamentals

ERAS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$51.33M
Free cash flow
-$32.82M
View full ERAS fundamental analysis

ERAS Technical Analysis

ERAS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
53.84
Price vs SMA-50
+4.70%
View full ERAS technical analysis

ERAS Stock Catalysts

Track ERAS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 11, 2027
Analyst target
—
News items
5
View ERAS earnings and stock catalysts

ERAS Dividend Analysis

ERAS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View ERAS dividend history and analysis

ERAS Financial Data

ERAS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.15
Periods
8
View ERAS financials

ERAS Risk Analysis

ERAS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.62
Risk score
39/100
1Y volatility
102.70%
View ERAS risk analysis

ERAS Stock News

ERAS stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read ERAS stock news

ERAS vs Biotechnology Peers

Current peer cohort: ERAS · EWTX · EXEL · FTRE · GMAB. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
ERAS
Current stock
61/100—67/10039/1002.29102.70%Current
EWTX
Edgewise Therapeutics, Inc.
72/100—82/10057/1001.4173.21%ERAS vs EWTX
EXEL
Exelixis, Inc.
82/10079/10091/10077/1001.533.90%ERAS vs EXEL
FTRE
Fortrea Holdings Inc.
75/10093/10088/10041/1001.2967.32%ERAS vs FTRE
GMAB
Genmab A/S
77/10071/10094/10058/1001.2945.85%ERAS vs GMAB
Pairwise Compare links: EWTX · EXEL · FTRE · GMABERAS vs EWTXERAS vs EXELERAS vs FTREERAS vs GMABCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a ERAS stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for ERAS: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-15.82
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0.05
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$51.33M
Quarter free cash flow
-$32.82M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Mixed
RSI 14
53.84
MACD
0.2

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
39/100
Beta
1.62
Annual volatility
102.70%
Max drawdown
-59.46%

ERAS Stock FAQ

What is ERAS stock price today?

Erasca, Inc.'s current stock price is $15.66. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is ERAS bullish or bearish right now?

ERAS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is ERAS's market cap?

ERAS's market cap is $5.39B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is ERAS's current P/E ratio?

ERAS's current P/E ratio is -15.82 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is ERAS's RSI?

ERAS's 14-day RSI is 53.84 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is ERAS above its 50-day and 200-day moving averages?

ERAS is 4.70% from its 50-day SMA and 2.65% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is ERAS's next earnings date?

ERAS's next earnings date is currently listed as Mar 11, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does ERAS pay a dividend?

ERAS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.